NASDAQ:CASI
CASI Pharmaceuticals Stock News
$3.30
+0.0550 (+1.69%)
At Close: May 17, 2024
23 Biotechnology Stocks Moving In Monday's After-Market Session
12:00am, Monday, 27'th Jan 2020What You Must Know About CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Beta Value
01:33pm, Sunday, 26'th Jan 2020
Anyone researching CASI Pharmaceuticals, Inc. (NASDAQ:CASI) might want to consider the historical volatility of the...
Have Insiders Been Buying CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Shares?
10:27am, Friday, 20'th Dec 2019
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
12:00am, Saturday, 07'th Dec 2019CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications
02:00am, Wednesday, 04'th Dec 2019
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announces that the China Nati
CASI Pharma's CD19 CAR-T clinical trial applications OK'd in China
12:00am, Wednesday, 04'th Dec 2019CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Path To Profitability
10:17am, Thursday, 14'th Nov 2019
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI): CASI Pharmaceuticals, Inc., a pharmaceutical company, develops...
CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results
12:00pm, Tuesday, 12'th Nov 2019
ROCKVILLE, Md. and BEIJING , Nov. 12, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharm
ROCKVILLE, Md. and BEIJING, Nov. 7, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and phar
Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
02:33pm, Wednesday, 06'th Nov 2019
Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.
